FIELD: biotechnology.
SUBSTANCE: invention relates to the invention is a diagnostic test system for the quantitative determination of mRNA levels of the mouse OAS1a/g, IL-6, IRF-7, IFNA, IFNB, IFNL genes by real-time PCR in a biological sample.
EFFECT: test system includes two samples-compositions in which several PCRs are carried out simultaneously, namely: in set I — determination of the expression levels of mouse genes OAS1a/g, IL-6, IRF-7 and GAPDH (normalization gene), in set II — determination of the expression level of mouse genes IFNA, IFNB, IFNL and GAPDH (normalization gene).
2 cl, 12 dwg, 2 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TEST SYSTEM FOR QUANTITATIVE DIAGNOSTICS OF HUMAN MRNA OF MXA, OAS1, EIF2AK2 GENES BASED ON PCR | 2022 |
|
RU2811690C1 |
| MULTIPARAMETRIC DIAGNOSTIC TEST SYSTEM FOR QUANTITATIVE DETERMINATION OF MRNA LEVEL OF HUMAN RIG-1, IFIT-1, IFIH-1 GENES | 2021 |
|
RU2782428C1 |
| TEST SYSTEM FOR QUANTITATIVE DIAGNOSIS OF MRNA OF HUMAN INTERFERON TYPE I, II AND III BASED ON PCR | 2020 |
|
RU2751791C1 |
| QUANTITATIVE METHOD FOR DETERMINING THE EXPRESSION OF GNAO1 ALLELES OF A HEALTHY FORM AND WITH c.607 G>A MUTATION | 2021 |
|
RU2777663C1 |
| ANALYTICAL TEST SYSTEM FOR DETERMINING SPECIFIC PATIENT'S MALIGNANT TUMOUR SENSITIVITY TO ONCOLYTIC BIOTHERAPY | 2017 |
|
RU2667648C1 |
| TEST SYSTEM FOR DETERMINATION OF INTERFERON, IL23 INTERLEUKINE AND MXA ANTI-VIRUS PROTEIN RNA | 2016 |
|
RU2627179C1 |
| EXPRESS TEST ON BASIS OF PCR, WHICH ENABLES TO PREDICT SENSITIVITY OF BRAIN TUMOR OF SPECIFIC PATIENT TO ONCOLYTIC VIRUSES | 2016 |
|
RU2697412C2 |
| KIT FOR DETERMINING THE ABUNDANCE OF THE APP GENE IN THE HUMAN GENOME | 2021 |
|
RU2789799C1 |
| A SET FOR DETERMING THE ABUNDANCE OF THE INSERTIONOF THE CONSTRUCT OF INTEREST INTO THE AAVS1LOCUS OF THE HUMAN GENOME | 2021 |
|
RU2786396C1 |
| KIT FOR DETERMINING CCR5DELTA32 MUTATIONS IN HUMAN GENOME | 2020 |
|
RU2748998C1 |
